Illicit Drug Use, Illicit Drug Use Disorders, and Drug Overdose Deaths in Metropolitan and Nonmetropolitan Areas—United States
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
PROBLEM/CONDITION: Drug overdoses are a leading cause of injury death in the United States, resulting in approximately 52,000 deaths in 2015. Understanding differences in illicit drug use, illicit drug use disorders, and overall drug overdose deaths in metropolitan and nonmetropolitan areas is important for informing public health programs, interventions, and policies. REPORTING PERIOD: Illicit drug use and drug use disorders during 2003-2014, and drug overdose deaths during 1999-2015. DESCRIPTION OF DATA: The National Survey of Drug Use and Health (NSDUH) collects information through face-to-face household interviews about the use of illicit drugs, alcohol, and tobacco among the U.S. noninstitutionalized civilian population aged ≥12 years. Respondents include residents of households and noninstitutional group quarters (e.g., shelters, rooming houses, dormitories, migratory workers' camps, and halfway houses) and civilians living on military bases. NSDUH variables include sex, age, race/ethnicity, residence (metropolitan/nonmetropolitan), annual household income, self-reported drug use, and drug use disorders. National Vital Statistics System Mortality (NVSS-M) data for U.S. residents include information from death certificates filed in the 50 states and the District of Columbia. Cases were selected with an underlying cause of death based on the ICD-10 codes for drug overdoses (X40-X44, X60-X64, X85, and Y10-Y14). NVSS-M variables include decedent characteristics (sex, age, and race/ethnicity) and information on intent (unintentional, suicide, homicide, or undetermined), location of death (medical facility, in a home, or other [including nursing homes, hospices, unknown, and other locations]) and county of residence (metropolitan/nonmetropolitan). Metropolitan/nonmetropolitan status is assigned independently in each data system. NSDUH uses a three-category system: Core Based Statistical Area (CBSA) of ≥1 million persons; CBSA of <1 million persons; and not a CBSA, which for simplicity were labeled large metropolitan, small metropolitan, and nonmetropolitan. Deaths from NVSS-M are categorized by the county of residence of the decedent using CDC's National Center for Health Statistics 2013 Urban-Rural Classification Scheme, collapsed into two categories (metropolitan and nonmetropolitan). RESULTS: Although both metropolitan and nonmetropolitan areas experienced significant increases from 2003-2005 to 2012-2014 in self-reported past-month use of illicit drugs, the prevalence was highest for the large metropolitan areas compared with small metropolitan or nonmetropolitan areas throughout the study period. Notably, past-month use of illicit drugs declined over the study period for the youngest respondents (aged 12-17 years). The prevalence of past-year illicit drug use disorders among persons using illicit drugs in the past year varied by metropolitan/nonmetropolitan status and changed over time. Across both metropolitan and nonmetropolitan areas, the prevalence of past-year illicit drug use disorders declined during 2003-2014. In 2015, approximately six times as many drug overdose deaths occurred in metropolitan areas than occurred in nonmetropolitan areas (metropolitan: 45,059; nonmetropolitan: 7,345). Drug overdose death rates (per 100,000 population) for metropolitan areas were higher than in nonmetropolitan areas in 1999 (6.4 versus 4.0), however, the rates converged in 2004, and by 2015, the nonmetropolitan rate (17.0) was slightly higher than the metropolitan rate (16.2). INTERPRETATION: Drug use and subsequent overdoses continue to be a critical and complicated public health challenge across metropolitan/nonmetropolitan areas. The decline in illicit drug use by youth and the lower prevalence of illicit drug use disorders in rural areas during 2012-2014 are encouraging signs. However, the increasing rate of drug overdose deaths in rural areas, which surpassed rates in urban areas, is cause for concern. PUBLIC HEALTH ACTIONS: Understanding the differences between metropolitan and nonmetropolitan areas in drug use, drug use disorders, and drug overdose deaths can help public health professionals to identify, monitor, and prioritize responses. Consideration of where persons live and where they die from overdose could enhance specific overdose prevention interventions, such as training on naloxone administration or rescue breathing. Educating prescribers on CDC's guideline for prescribing opioids for chronic pain (Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain-United States, 2016. MMWR Recomm Rep 2016;66[No. RR-1]) and facilitating better access to medication-assisted treatment with methadone, buprenorphine, or naltrexone could benefit communities with high opioid use disorder rates.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
CDC Guideline for Prescribing Opioids for Chronic Pain—United States, 2016
Dowell, D., Haegerich, T. M., & Chou, R. (2016) · JAMA · doi:10.1001/jama.2016.1464 · Cited by 5,161 · cited 2×
“In addition, the following resources can assist providers and communities in efforts to reduce misuse and overdose: • CDC’s rural health website (https://www.cdc.gov/rural health/) and the Guideline for Prescribing Opioids for Chronic Pain resource page (https://www.cdc.gov/drug overdose/prescribing/resources.html; •…”
2013 NCHS Urban-Rural Classification Scheme for Counties.
Ingram, D. D., & Franco, S. J. (2012) · PubMed · Cited by 1,762
Vital signs: overdoses of prescription opioid pain relievers---United States, 1999--2008.
Paulozzi, L. J., Jones, C. M., Mack, K. A., & Rudd, R. A. (2011) · PubMed · Cited by 1,540
Self-citationVital signs: changes in opioid prescribing in the United States, 2006-2015.
Guy, G. P., Zhang, K., Bohm, M. K., Losby, J., Lewis, B., Young, R., Murphy, L. B., & Dowell, D. (2017) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6626a4 · Cited by 1,117
Vital Signs: Demographic and Substance Use Trends Among Heroin Users - United States, 2002-2013.
Jones, C. M., Logan, J. E., Gladden, R. M., & Bohm, M. K. (2015) · PubMed Central · Cited by 569
Self-citationVan Handel, M. M., Rose, C. E., Hallisey, E. J., Kolling, J. L., Zibbell, J. E., Lewis, B., Bohm, M. K., Jones, C. M., Flanagan, B. E., Siddiqi, A.-E.-A., et al. (2016) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000001098 · Cited by 438 · cited 1×
“Access to substance abuse treatment services is more limited in rural areas (27) and strengthening the health care delivery system while improving the integration of primary, specialty, and substance abuse services can provide the nexus of care needed to reduce drug misuse (28–31).”
Self-citationNew Data on Opioid Use and Prescribing in the United States
Schuchat, A., Houry, D., & Guy, G. P. (2017) · JAMA · doi:10.1001/jama.2017.8913 · Cited by 326 · cited 1×
“Reducing the number of persons initially exposed to prescription opioids might reduce the illicit use of opioids, the subsequent risk of addiction, and the use of illicit drugs (22).”
Leading Causes of Death in Nonmetropolitan and Metropolitan Areas— United States, 1999–2014
Moy, E., Garcia, M. C., Bastian, B., Rossen, L. M., Ingram, D. D., Faul, M., Massetti, G. M., Thomas, C. C., Hong, Y., Yoon, P. W., et al. (2017) · MMWR. Surveillance Summaries · doi:10.15585/mmwr.ss6601a1 · Cited by 319 · cited 1×
“During 1999–2014, annual age-adjusted death rates for the five leading causes of death in the United States (heart disease, cancer, unintentional injury, chronic lower respiratory disease, and stroke) were higher in rural (nonmetropolitan) areas than in urban (metropolitan) areas (1).”
Paulozzi, L. J., & Xi, Y. (2008) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1626 · Cited by 283
Des Jarlais, D. C., Nugent, A., Solberg, A., Feelemyer, J., Mermin, J., & Holtzman, D. (2015) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6448a3 · Cited by 248 · cited 1×
“Further, given research indicating that nonmetropolitan areas have less access to substance abuse treatment services (18) and other risk reduction strategies (19), the similar prevalence of drug use disorders in this study underscores the importance of scaling up these critical interventions in nonmetropolitan areas.”
Cited by
Clinical Practice Guidelines for Pain Management in Acute Musculoskeletal Injury
Hsu, J. R., Mir, H., Wally, M. K., Seymour, R. B., & the Orthopaedic Trauma Association Musculoskeletal Pain Task Force (2019) · Journal of Orthopaedic Trauma · doi:10.1097/bot.0000000000001430 · Cited by 280
Lister, J. J., Weaver, A., Ellis, J. D., Himle, J. A., & Ledgerwood, D. M. (2020) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990.2019.1694536 · Cited by 253
Lippold, K. M., Jones, C. M., Olsen, E. O., & Giroir, B. P. (2019) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6843a3 · Cited by 204
Self-citationTrends in Emergency Department Use by Rural and Urban Populations in the United States
Greenwood-Ericksen, M. B., & Kocher, K. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.1919 · Cited by 204
Shiels, M. S., Berrington de González, A., Best, A. F., Chen, Y., Chernyavskiy, P., Hartge, P., Khan, S. Q., Pérez-Stable, E. J., Rodriquez, E. J., Spillane, S., et al. (2019) · The Lancet Public Health · doi:10.1016/s2468-2667(18)30208-1 · Cited by 61
D'Amico, E. J., Dickerson, D. L., Brown, R. A., Johnson, C. L., Klein, D. J., & Agniel, D. (2020) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2019.12.011 · Cited by 59
Surratt, H. L., Otachi, J. K., Williams, T., Gulley, J., Lockard, A. S., & Rains, R. (2020) · The Journal of Rural Health · doi:10.1111/jrh.12388 · Cited by 18
Palacios-Ceña, D., Jiménez-Trujillo, I., Hernández-Barrera, V., Lima Florencio, L., & Carrasco-Garrido, P. (2019) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph16183423 · Cited by 13
Metadata
- Authors
- Mack, K. A., Jones, C. M., & Ballesteros, M. F.
- Venue
- American Journal of Transplantation
- Publisher
- Elsevier BV
- Published
- 2017-12
- Volume
- 17
- Issue
- 12
- Pages
- 3241-3252
- ISSN
- 1600-6135 (ISSN-L)
- OpenAlex
- W2768230508
- Cited by
- 168
- References
- 24
- FWCI
- 17.67
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.